EUVIMEDEUVIMED entdecken
Crossref

Prediction of Recurrent Venous Thromboembolism and Arterial Cardiovascular Events after Discontinuation of Anticoagulation: The R-VTE-predict and MACE-predict Risk Scores

Vorhersage von rezidivierender venöser Thromboembolie und arteriellen kardiovaskulären Ereignissen nach Absetzen der Antikoagulation: die Risikoscores R-VTE-predict und MACE-predict

Steve R Noumegni, Benjamin Espinasse, Romain Didier, Raphael Le Mao, Claire De Moreuil, Cécile Tromeur, Emmanuelle Le Moigne, Pierre-Yves Le Roux, Francis Couturaud

Seminars in Thrombosis and Hemostasis · 2025-10 · 51 (07) · 788-799

DOI: 10.1055/s-0045-1807262 ↗

Auf einen Blick

Zwei einfache Risikoscores wurden entwickelt, um nach Absetzen der Antikoagulation das Risiko für rezidivierende VTE und MACE nach VTE abzuschätzen. In der Validierung zeigte sich eine brauchbare Diskriminierung.

Fragestellung

Lassen sich rezidivierende VTE und MACE nach Absetzen der Antikoagulation mit einfachen klinischen Risikoscores vorhersagen?

Methode

Entwicklung und Validierung von Risikoscores in der EDITH-Kohorte; unabhängige Prädiktoren aus multivariablen Cox-Modellen; Validierung per Bootstrapping.

Ergebnisse

1.999 Teilnehmende in der Ableitungskohorte und 10.000 in der Validierung. Nach median 6,9 Jahren traten rezidivierende VTE bei 29,5 % und MACE bei 14,8 % auf. Höhere Risikogruppen zeigten steigende HRs; C-Statistik 0,62–0,63 bzw. 0,72–0,77.

Einschränkungen

Die Autor:innen weisen darauf hin, dass weitere Studien zur Bestätigung nötig sind.

Schlussfolgerung der Autor:innen

Einfachen, auf klinischen Merkmalen basierenden Risikoscores können das Risiko für rezidivierende VTE und MACE nach Absetzen der Antikoagulation reasonably vorhersagen.

Kernaussagen

  • 29,5 % rezidivierende VTE und 14,8 % MACE nach median 6,9 Jahren
  • Höheres Risiko in den Score-Gruppen mit steigenden HRs
  • Validierung mit C-Statistik 0,62–0,63 bzw. 0,72–0,77

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 09.04.2025. Verfasst von Steve R Noumegni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Cardiovascular Research Center, University of Florida College of Medicine, Jacksonville, Florida. Hauptthemen laut MEDLINE: Venous Thromboembolism, Anticoagulants, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients who had venous thromboembolism (VTE) are not only at increased risk of recurrent VTE but also of major adverse cardiovascular events (MACEs) than the general population. Therefore, the prediction of the risk of these events is important for a tailored prevention and mitigation strategy. We aimed to develop simple scores to estimate recurrent VTE and MACE risks after the discontinuation of anticoagulation in a large cohort of individuals who suffered VTE (EDITH cohort). The primary endpoints were recurrent symptomatic VTE and MACE (composite of non-fatal acute coronary syndrome, stroke and cardiovascular death). Arterial thrombotic event (ATE) exclusively was also considered. Independent predictors of main outcomes were derived from multivariable Cox regression models. Weighted integer points based on the effect estimate of identified predictors were used to derive the final risk scores. A total of 1,999 participants (mean age: 54.78 years, 46.4% male, 43.6% unprovoked VTE) were included in the derivation cohort and 10,000 in the validation cohort (built using bootstrapping). During a median post-anticoagulation follow-up of 6.9 years, recurrent VTE occurred in 29.5% of participants and MACE in 14.8%. Independent predictors of recurrent VTE were male sex, age >65 years, cancer-associated VTE, and unprovoked VTE (vs. transient risk factor-associated VTE). Independent predictors of MACE were age >65 years, cancer-associated VTE, hypertension, renal insufficiency, and atrial fibrillation. The risk of recurrent VTE (moderate vs. low: hazard ratio [HR]: 2.62, 95% confidence interval [CI]: 2.06–3.34; high vs. low: HR: 3.78, 95% CI: 2.91–4.89), MACE (moderate vs. low: HR: 6.37, 95% CI: 3.19–12.69; high vs. low: HR: 12.32, 95% CI: 6.09–24.89), and ATE (based on MACE-predict risk score) increased gradually from the lowest to highest of the respective prediction risk score groups. These results were confirmed in the validation cohort with overall reasonable models' discrimination performance (recurrent VTE C-statistic: 0.62–0.63, MACE and ATE C-statistic: 0.72–0.77). Contemporary simple risk scores based on readily available clinical characteristics can reasonably predict the risk of recurrent VTE and MACE after the discontinuation of anticoagulation. These findings may influence the choice of anticoagulation strategy after the acute phase of VTE and, therefore, need confirmation by further studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismAnticoagulantsCardiovascular DiseasesHumansMaleFemaleMiddle AgedRecurrenceRisk FactorsAgedAdultRisk Assessment

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Division of Cardiology, Cardiovascular Research Center, University of Florida College of Medicine, Jacksonville, Florida.
  • Inserm, UMR 1304 (GETBO), University of Brest, France.
  • Internal Medicine, Vascular Medicine and Pneumology Department, CHU Brest, Brest, France.
  • Cardiology Department, CHU Brest, Brest, France.
  • Department of Nuclear Medicine, CHU Brest, Brest, France.

Zitieren

APA

Noumegni, S. R., Espinasse, B., Didier, R., Mao, R. L., Moreuil, C., Tromeur, C., Moigne, E. L., Roux, P. L., & Couturaud, F. (2025). Prediction of Recurrent Venous Thromboembolism and Arterial Cardiovascular Events after Discontinuation of Anticoagulation: The R-VTE-predict and MACE-predict Risk Scores. Seminars in Thrombosis and Hemostasis, 51(07), 788-799. https://doi.org/10.1055/s-0045-1807262

Vancouver

Noumegni SR, Espinasse B, Didier R, Mao RL, Moreuil C, Tromeur C, et al. Prediction of Recurrent Venous Thromboembolism and Arterial Cardiovascular Events after Discontinuation of Anticoagulation: The R-VTE-predict and MACE-predict Risk Scores. Seminars in Thrombosis and Hemostasis. 2025;51(07):788-799. doi:10.1055/s-0045-1807262

BibTeX
@article{Noumegni2025,
  author = {Noumegni, Steve R and Espinasse, Benjamin and Didier, Romain and Mao, Raphael Le and Moreuil, Claire De and Tromeur, Cécile and Moigne, Emmanuelle Le and Roux, Pierre-Yves Le and Couturaud, Francis},
  title = {Prediction of Recurrent Venous Thromboembolism and Arterial Cardiovascular Events after Discontinuation of Anticoagulation: The R-VTE-predict and MACE-predict Risk Scores},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2025},
  volume = {51},
  number = {07},
  pages = {788--799},
  doi = {10.1055/s-0045-1807262}
}
Kostenlos starten →